Toulouse

Principal investigator:
Prof. Olivier Rascol

Toulouse III University
Laboratoire de Pharmacologie
Faculte de Medecine 37 Allees Jules Guesde
F-31073 Toulouse
rascol(at)cict.fr

Prof. Anne Pavy-Le Traon

Department of Neurology, French Reference Centre for Multiple System Atrophy, University Hospital of Toulouse.

UMR INSERM 1048, Toulouse, France.

Expertise of the participating organization:

The group is directly part of a number of complementary and multidisciplinary units which are all involved in the clinical management and research of patients with Parkinson's disease. The main activities and facilities are :
- The Clinical Research Centre (INSERM-Toulouse Hospital) with a team (doctors, nurses, pharmacists, technicians...) dedicated to clinical research with a special competence in pharmacology and drug development
- The Movement Disorders Clinic of the Department of Neurology, which is following-up several hundreds of patients with parkinsonism
- The Autonomic Nervous System Unit of the Department of Neurology which is following several hundreds of patients with dysautonomia
- The Neuroimaging Unit (INSERM U455) which offers MRI, SPECT and PET facilities

Recent publications relevant to the EMSA-SG:

Barbagallo G, Sierra-Pena M, Nemmi F, Traon AP, Meissner WG, Rascol O, Peran P. Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease. Mov Disord 2016;31:325-334.

Ratti PL, Sierra-Pena M, Manni R, Simonetta-Moreau M, Bastin J, Mace H, Rascol O, David O. Distinctive features of NREM parasomnia behaviors in parkinson's disease and multiple system atrophy. PLoS One 2015;10:e0120973.

Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA, Giladi N, Barone P, Sampaio C, Eyal E, Rascol O, Rasagiline-for MSAi. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol 2015;14:145-152.

Rey MV, Perez-Lloret S, Pavy-Le Traon A, Meissner WG, Tison F, Rascol O. A cross-sectional study on drug use in multiple system atrophy. CNS Drugs 2014;28:483-490.

Payoux P, Brefel-Courbon C, Ory-Magne F, Regragui W, Thalamas C, Balduyck S, Durif F, Azulay JP, Tison F, Blin O, Esquerre JP, Rascol O. Motor activation in multiple system atrophy and Parkinson disease: a PET study. Neurology 2010;75:1174-1180.

Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol 2008; 65: 577-83.

Pavy-Le Traon A, Hughson RL, Thalamas C, Galitsky M, Fabre N, Rascol O, et al. Cerebral autoregulation is preserved in multiple system atrophy: A transcranial Doppler study. Mov Disord 2006; 21: 2122-6. 

Rascol O. Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: an important but still unmet need. Mov Disord 2006; 21: 1059-61.

Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. Mov Disord 2006; 21: 2110-5. 

Rascol O, Brefel-Courbon C, Payoux P, Ferreira J. The management of patients with early Parkinson's disease. Adv Neurol 2003; 91: 203-11. 

Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002; 359: 1589-98. 

Senard JM, Brefel-Courbon C, Rascol O, Montastruc JL. Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging 2001; 18: 495-505.